Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UroGen Pharma Ltd.URGN · Entity 4466 | Chief Medical Officer | September 07, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UroGen Pharma Ltd.
Report date September 07, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 59,882 |
Ending reported balance
After 2026-09-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-07 · Exercise / conversion · Acquired 1,667 · Balance 60,753 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Row 2 · 2026-09-08 · Sale · Disposed 871 · Balance 59,882 F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-07 · Exercise / conversion · Disposed 1,667 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3: The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3: The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2024 Filed Feb 3, 2024 00:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-003016 · rdgdoc.xml · derivative · entry 10 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F6 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2025, January 31, 2026 and January 31, 2027. F6 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2025, January 31, 2026 and January 31, 2027. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-003016 · rdgdoc.xml · derivative · entry 9 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Ordinary Shares · 3,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024. F5 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 1,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-003016 · rdgdoc.xml · derivative · entry 8 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,334 Underlying: Ordinary Shares · 1,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023. F4 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-003016 · rdgdoc.xml · derivative · entry 7 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022. F3 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,894 | $15.74 | $29,811.56 |
DisclosureSEC source: 0001437749-24-003016 · rdgdoc.xml · nonDerivative · entry 6 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,437 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 3,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-003016 · rdgdoc.xml · nonDerivative · entry 5 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 758 | $15.74 | $11,930.92 |
DisclosureSEC source: 0001437749-24-003016 · rdgdoc.xml · nonDerivative · entry 4 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,998 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-003016 · rdgdoc.xml · nonDerivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,137 | $15.74 | $17,896.38 |
DisclosureSEC source: 0001437749-24-003016 · rdgdoc.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,423 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-003016 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| September 07, 2023 Filed Sep 8, 2023 19:40 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-025476 · rdgdoc.xml · derivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Ordinary Shares · 5,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F2 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of September 7, 2024, September 7, 2025 and September 7, 2026 F2 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of September 7, 2024, September 7, 2025 and September 7, 2026 Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 19:26 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-017046 · rdgdoc.xml · derivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2023. F2 · derivative.expiration_date: The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2023. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:02 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001437749-23-002336 · rdgdoc.xml · derivative · entry 11 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires 2033-01-31 F6 · derivative.exercise_date: 1/3 of the shares underlying the stock options will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:02 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-002336 · rdgdoc.xml · derivative · entry 10 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026. F5 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:02 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 1,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-002336 · rdgdoc.xml · derivative · entry 9 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,667 Underlying: Ordinary Shares · 1,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023. F4 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:02 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-002336 · rdgdoc.xml · derivative · entry 8 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Ordinary Shares · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022. F3 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:02 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-002336 · rdgdoc.xml · derivative · entry 7 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F2 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:02 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 661 | $10.12 | $6,689.32 |
DisclosureSEC source: 0001437749-23-002336 · rdgdoc.xml · nonDerivative · entry 6 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,560 F7 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:02 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-002336 · rdgdoc.xml · nonDerivative · entry 5 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:02 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 991 | $10.12 | $10,028.92 |
DisclosureSEC source: 0001437749-23-002336 · rdgdoc.xml · nonDerivative · entry 4 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,888 F7 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:02 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-002336 · rdgdoc.xml · nonDerivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:02 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 248 | $10.12 | $2,509.76 |
DisclosureSEC source: 0001437749-23-002336 · rdgdoc.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,879 F7 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:02 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-002336 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 00:10 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 122,677 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001437749-23-001625 · rdgdoc.xml · derivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 122,677 shares Expires 2023-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 00:10 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 122,677 | $5.00 | $613,385.00 |
DisclosureSEC source: 0001437749-23-001625 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 20:31 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-025549 · rdgdoc.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Underlying: Ordinary Shares · 500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 20:31 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 258 | $11.85 | $3,057.30 |
DisclosureSEC source: 0001437749-22-025549 · rdgdoc.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,950 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 20:31 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-025549 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document |
| August 01, 2022 Filed Aug 25, 2022 19:25 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 259 | $7.81 | $2,022.79 |
DisclosureSEC source: 0001437749-22-021337 · rdgdoc.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,708 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| July 31, 2022 Filed Aug 25, 2022 19:25 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-021337 · rdgdoc.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Ordinary Shares · 500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| July 31, 2022 Filed Aug 25, 2022 19:25 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-021337 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document |
| April 30, 2022 Filed May 3, 2022 21:19 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-010701 · rdgdoc.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Ordinary Shares · 500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| April 30, 2022 Filed May 3, 2022 21:19 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 254 | $6.62 | $1,681.48 |
DisclosureSEC source: 0001437749-22-010701 · rdgdoc.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,467 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| April 30, 2022 Filed May 3, 2022 21:19 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-010701 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:33 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006384 · doc4.xml · derivative · entry 8 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Ordinary Shares · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F6 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022. F6 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:33 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006384 · doc4.xml · derivative · entry 7 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Ordinary Shares · 0 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F5 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025 F5 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025 Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:33 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (right to buy) · Derivative | 12,064 | $0.00 Strike: $7.72 | $0.00 |
DisclosureSEC source: 0001209191-22-006384 · doc4.xml · derivative · entry 6 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,064 Underlying: Ordinary Shares · 12,064 shares Expires 2032-01-31 F4 · derivative.exercise_date: 1/3 of the shares underlying the stock options will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025 Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:33 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006384 · doc4.xml · derivative · entry 5 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Ordinary Shares · 500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:33 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,099 | $7.58 | $8,330.42 |
DisclosureSEC source: 0001209191-22-006384 · doc4.xml · nonDerivative · entry 4 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,221 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:33 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-006384 · doc4.xml · nonDerivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:33 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 275 | $7.58 | $2,084.50 |
DisclosureSEC source: 0001209191-22-006384 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,320 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:33 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-006384 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:29 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 209 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005416 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 209 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:29 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 111 | $8.09 | $897.99 |
DisclosureSEC source: 0001209191-22-005416 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,095 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:29 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 209 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-005416 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 20:05 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | PurchaseOrdinary Shares | 160 | $13.10 | $2,096.00 |
DisclosureSEC source: 0001209191-21-065756 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,997 Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 19:45 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 258 | $17.16 | $4,427.28 |
DisclosureSEC source: 0001209191-21-062360 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,837 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units Read SEC document |
| October 31, 2021 Filed Nov 2, 2021 19:45 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062360 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Ordinary Shares · 500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| October 31, 2021 Filed Nov 2, 2021 19:45 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-062360 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document |
| October 27, 2021 Filed Oct 28, 2021 18:04 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 107 | $16.32 | $1,746.24 |
DisclosureSEC source: 0001209191-21-061868 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,595 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.